IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma

American Journal of Pathology

Volumn 175, Issue 2, 2009, Pages 825-834

  Bard, Jennifer Dien ^a   Gelebart, Pascal ^a   Anand, Mona ^a   Zak, Zoulika ^a   Hegazy, Samar A ^a   Amin, Hesham M ^b   Lai, Raymond ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; JANUS KINASE 3; MESSENGER RNA; NUCLEOPHOSMIN; PARAFFIN; SMALL INTERFERING RNA; STAT3 PROTEIN;

ARTICLE; CELL GROWTH; CELL STIMULATION; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; FROZEN SECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LARGE CELL LYMPHOMA; LYMPHOID CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 68449086508     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080982     Document Type: Article

References (51)

1. Amin HM, Lai R: Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007, 110:2259-2267
2. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT: Fusion of a kinase gene. ALK, to a nucleolar protein gene NPM, in non-Hodgkin's lymphoma. Science 1994, 263:1281-1284
3. Shiota M, Fujimoto J, Takenaga M, Satoh H, Ichinohasama R, Abe M, Nakano M, Yamamoto T, Mori S: Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 1994, 84:3648-3652
4. Amin HM, Medeiros LJ, Ma Y, Feretzaki M, Das P, Leventaki V, Rassidakis GZ, O'Connor SL, McDonnell TJ, Lai R: Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 2003, 22:5399-5407
5. Bischof D, Pulford K, Mason DY, Morris SW: Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997, 17:2312-2325
6. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, Karras JG, Levy DE, Inghirami G: Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005, 11:623-629
7. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S, Yamamoto T: Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA: 1996, 93:4181-4186
8. Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA, Skorski T: Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001, 61:2194-2199
9. Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene 2000, 19:2474-2488
10. Darnell JE, Jr.: Stats and Gene Regulation. Science 1997, 277:1630-1635
11. Mahboubi K, Li F, Plescia J, Kirkiles-Smith NC, Mesri M, Du Y, Carroll JM, Elias JA, Altieri DC, Pober JS: Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab Invest 2001, 81:327-334
12. Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, Schmitt-Graeff A, Herling M, Amin HM, Lai R: Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res 2003, 9:3692-3699
13. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE, Inghirami G: Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002, 21:1038-1047
14. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T, Wasik MA: Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 2002, 168:466-474
15. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE, Jr.: Stat3 as an oncogene. Cell 1999, 98:295-303
16. Burke WM, Jin X, Lin HJ, Huang M, Liu R, Reynolds RK, Lin J: Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001, 20:7925-7934
17. Levy DE, Darnell JE, Jr.: Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3:651-662
18. Lin TS, Mahajan S, Frank DA: STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000, 19:2496-2504
19. Ma XT WS, Ye YJ, Du RY, Cui ZR, Somsouk M: Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol 2004, 10:1569-1573
20. Coqueret O, Gascan H: Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1. J Biol Chem 2000, 275:18794-18800
21. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran TP, Jr.: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001, 107:351-362
22. Grad JM, Zeng XR, Boise LH: Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Curr Opin Oncol 2000, 12:543-549
23. Amin HM MT, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Cutler C, Medeiros LJ, Lai R: Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004, 23:5426-5434
24. Qiu L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D, Ford RJ, Kwak LW, Kirken RA, Amin HM: Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 2006, 108:2407-2415
25. Fujitani Y, Hibi M, Fukada T, Takahashi-Tezuka M, Yoshida H, Yamaguchi T, Sugiyama K, Yamanaka Y, Nakajima K, Hirano T: An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT. Oncogene 1997, 14:751-761
26. Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R: Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 2006, 108:2796-2803
27. Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D, Sugamura K: Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001, 167:1-5
28. Habib T, Senadheera S, Weinberg K, Kaushansky K: The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 2002, 41:8725-8731
29. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M, Brandt C, Kuijper JL, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F, Bort S, Hambly K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton-Day C, Gilbert T, Rayond F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Maurer M, Kaushansky K, Holly RD, Foster D: Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63
30. Leonard WJ: Cytokines and immunodeficiency diseases. Nat Rev Immunol 2001, 1:200-208
31. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, Ugazio AG, Johnston JA, Candotti F, O'Shea JJ, Vezzoni P, Notarangelo LD: Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995, 377:65-68
32. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, O'Shea JJ, Leonard WJ: Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995, 270:797-800
33. Habib T, Nelson A, Kaushansky K: IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J Allergy Clin Immunol 2003, 112:1033-1045
34. Strengell M, Sareneva T, Foster D, Julkunen I, Matikainen S: IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol 2002, 169:3600-3605
35. Suto A, Nakajima H, Hirose K, Suzuki K, Kagami S, Seto Y, Hoshimoto A, Saito Y, Foster DC, Iwamoto I: Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C(epsilon) transcription of IL-4-stimulated B cells. Blood 2002, 100:4565-4573
36. Mehta DS, Wurster AL, Whitters MJ, Young DA, Collins M, Grusby MJ: IL-21 induces the apoptosis of resting and activated primary B cells. J Immunol 2003, 170:4111-4118
37. Li Y, Bleakley M, Yee C: IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005, 175:2261-2269
38. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, Berzofsky JA, Leonard WJ: Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005, 201:139-148
39. Akamatsu N, Yamada Y, Hasegawa H, Makabe K, Asano R, Kumagai I, Murata K, Imaizumi Y, Tsukasaki K, Tsuruda K, Sugahara K, Atogami S, Yanagihara K, Kamihira S: High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma. Cancer Lett 2007, 256:196-206
40. Brenne AT, Ro TB, Waage A, Sundan A, Borset M, Hjorth-Hansen H: Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 2002, 99:3756-3762
41. Ueda M, Imada K, Imura A, Koga H, Hishizawa M, Uchiyama T: Expression of functional interleukin-21 receptor on adult T-cell leukaemia cells. Br J Haematol 2005, 128:169-176
42. de Totero D, Meazza R, Zupo S, Cutrona G, Matis S, Colombo M, Balleari E, Pierri I, Fabbi M, Capaia M, Azzarone B, Gobbi M, Ferrarini M, Ferrini S: Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood 2006, 107:3708-3715
43. Pelletier M, Bouchard A, Girard D: In vivo and in vitro roles of IL-21 in inflammation. J Immunol 2004, 173:7521-7530
44. Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, Smyth MJ, Godfrey DI: IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007, 178:2827-2834
45. Kasaian MT, Whitters MJ, Carter LL, Lowe LD, Jussif JM, Deng B, Johnson KA, Witek JS, Senices M, Konz RF, Wurster AL, Donaldson DD, Collins M, Young DA, Grusby MJ: IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002, 16:559-569
46. Scheeren FA DS, Smit LA, Beaumont T, Naspetti M, Bende RJ, Blom B, Karube K, Ohshima K, van Noesel CJ, Spits H: IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 2008, 111:4706 -4715
47. Lamprecht B, Kreher S, Anagnostopoulos I, Johrens K, Monteleone G, Jundt F, Stein H, Janz M, Dorken B, Mathas S: Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 2008, 112:3339-3347
48. Crockett DK, Lin Z, Elenitoba-Johnson KS, Lim MS: Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 2004, 23:2617-2629
49. Wu F, Wang P, Young LC, Lai R, Li L: Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein. NPMALK, using tandem affinity purification and mass spectrometry. Am J Pathol 2009, 174:361-370
50. Zeng R, Spolski R, Casas E, Zhu W, Levy DE, Leonard WJ: The molecular basis of IL-21-mediated proliferation. Blood 2007, 109:4135-4142
51. Adamkova L, Souckova K, Kovarik J: Transcription protein STAT1: biology and relation to cancer. Folia Biol (Praha) 2007, 53:1-6